86 results about "Viral Genes" patented technology

The invention provides a virus propagation dynamic prediction method based on a multi-strain multi-region population model and related equipment. The method comprises the following steps: acquiring historical epidemic situation related data of a target area, wherein the historical epidemic situation related data comprises epidemic situation data, virus gene sequence data, population flow data and epidemic situation management policy data related to a target virus in a past time period of each area; arranging the population flow data into an asymmetric population flow matrix between different regions every day; sorting epidemic prevention grades corresponding to different epidemic situation management policies according to the epidemic situation management policy data; and constructing a multi-strain and multi-region population model based on epidemic situation data, virus gene sequence data, a population flow matrix and epidemic prevention grades corresponding to different epidemic situation management policies by taking StatPOMP as a model construction framework, and generating virus propagation dynamic prediction information based on the model. The prediction accuracy of the virus propagation trend can be improved.

The invention discloses a live pig epidemic prevention and control flow regulation system and method based on big data, and relates to the technical field of animal health information, and the method comprises the steps: recognizing abnormal live pig signals and track intersection features of structured epidemic prevention feature data through an intelligent algorithm, comparing the virus gene difference degree, constructing a virus propagation network diagram, and carrying out the analysis of the virus propagation network diagram; outputting a high-risk propagation node map; constructing an aerosol dynamics three-dimensional space model by taking a super propagation hub node of the high-risk propagation node map as an original point and combining culture environment parameters, simulating a virus air diffusion path, and generating an environment propagation thermal distribution map; fusing the high-risk propagation node map and the environment propagation thermal distribution map, identifying a cross infection area through a multi-dimensional risk superposition model to perform risk dynamic grading, and outputting a grading early warning report; according to the invention, breakthrough improvement of the live pig epidemic prevention and control capability is realized, key nodes and potential risk areas of epidemic propagation can be accurately identified, and the pertinence of prevention and control measures is improved.

The present invention relates to a viral gene therapy vector for removing hepatitis B viruses, a preparation method therefor, and the use thereof, aiming to solve the problem in which existing viral gene therapy vectors can only inhibit the replication of hepatitis B viruses, but cannot remove virus cccDNA. The vector comprises a promoter, an intron, an enhancer, a nuclear localization signal (NLS) functional domain encoding gene of PGLYRP2 protein, an HBV DNA binding domain encoding gene of the PGLYRP2 protein, a secretory signal peptide functional domain encoding gene of the PGLYRP2 protein, an HBV nucleocapsid-binding functional domain encoding gene of the PGLYRP2 protein, and an IRES fragment. The viral gene therapy vector can remarkably promote the removal of HBVs in the liver of mice and is used for treatment of hepatitis B virus infection.

The present invention relates to methods of producing microbubble drug conjugates, viral gene therapy microbubble drug conjugates, and disease-targeting microbubbles, for clinical and preclinical ultrasound-mediated therapeutic and diagnostic applications. It includes methods to produce viral vector gene therapy microbubble drug conjugates with antibody linkers conjugated to lipid shelled microbubbles that both bind to and neutralize viral vectors such that the viral gene therapy can transduce and effect permanent genetic changes only after ultrasound is used to disassociate the viral gene therapy from microbubbles at diseased regions of the body.

The disclosure relates to block copolymer nanoparticles for therapeutic delivery of nucleic acids, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering miRNAs.

The invention discloses a fiveleaf virus GI.2 whole genome sequencing primer based on an amplicon sequencing technology and application thereof, and belongs to the technical field of virus gene sequencing. The primer group composed of 18 pairs of primers is preferably obtained according to an amplicon sequencing technology, the primer group can effectively improve the primer amplicon coverage degree, it is guaranteed that the primer amplicon coverage degree is 1.5-1.8 times that of a virus sequence, the amplification time is shortened, the amplification difficulty is reduced, the primer amplicon coverage degree and the whole genome capture efficiency are improved, and the primer amplification efficiency is improved. And the method has important significance on epidemic situation traceability and propagation trend of the fiveleaf virus GI.2.

The disclosure relates to block copolymer nanoparticles for therapeutic delivery of nucleotides, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering miRNAs.

The invention discloses a virus gene sequence host prediction method and system, and belongs to the technical field of biological information analysis, and the method comprises the steps: dividing a virus gene sequence into ordered k-mer word sequences, and carrying out the vectorization of the k-mer word sequences through a pre-trained BERT language model, and obtaining an embedded vector; mapping the embedded vector of the high-dimensional space into a low-dimensional space with a fixed dimension by adopting an average pooling method, and reducing the embedded dimension to obtain a feature vector representing an original gene sequence; the feature vectors are input into a pre-trained classification network model to predict the likelihood that the sequence is infected with a particular host. According to the method, the complete virus gene sequence is directly used as input, so that information loss possibly caused by dependence on statistical characteristics is avoided, and the accuracy of characteristic extraction is remarkably improved.

The invention provides a rapid processing method for HPV (human papillomavirus) gene sequence data. The method relates to the technical field of data processing, and comprises the following steps: acquiring and integrating HPV sequence data, host transcriptome data and clinical association data to form a comprehensive input matrix; performing feature screening on the comprehensive input matrix by adopting a bee colony optimization algorithm based on reinforcement learning to obtain an optimal feature subset; according to the bee colony optimization algorithm, global search of the bee colony algorithm is combined with a dynamic decision-making mechanism of reinforcement learning, and a feature selection strategy is dynamically adjusted; and constructing an HPV subtype accurate typing and variation detection model based on multi-task deep learning, performing deep coding and weighted fusion on the optimal feature subset through an unstable attention mechanism, and outputting two key prediction results of subtype probability and mutation site probability. According to the method, the accuracy and biological interpretability of virus typing and variation detection are improved, and efficient extraction and multi-task accurate recognition of high-dimensional features are realized.

Herein is reported a method for producing a recombinant adeno-associated viral particle preparation (rAAVp), the method comprising the steps of culturing a mammalian cell comprising an expression cassette directed against: a non-adeno-associated viral gene interposed between two AAV inverted terminal repeats (ITRs), and thereby producing the rAAVp; an adeno-associated virus rep gene; an adeno-associated virus cap gene; an adeno-associated virus E1A gene; an adeno-associated virus E1B gene; an adeno-associated virus E2A gene; an adeno-associated virus E4orf6; and an adeno-associated virus VA RNA gene, wherein the culturing is carried out at a pH value in the range of pH 7.4 to pH 7.6 and including a terminal value. The yield of the rAAVp produced by the culture performed at a pH value in the range of pH 7.4 to pH 7.6 and including a terminal value is higher than the yield of the rAAVp produced by the culture performed at a pH value in the range of pH 7.0 to pH 7.2 and including a terminal value, and the yield of the rAAVp produced by the culture performed at a pH value in the range of pH 7.4 to pH 7.6 and including a terminal value is lower than the yield of the rAAVp produced by the culture performed at a pH value in the range of pH 7.0 to pH 7.2. And the rAAVp produced by the culture at a pH value in the range of pH 7.4 to pH 7.6 and including an endvalue has a higher percentage of intact particles than the rAAVp produced by the culture at a pH value in the range of pH 7.0 to pH 7.2 and including an endvalue.

The invention provides a vector and a method for expressing astaxanthin by using nicotiana benthamiana leaves, which are characterized in that plant virus expression vectors of calendula astaxanthin synthesis related genes AdKC and AdKeto and plant virus gene silencing (RNAi) vectors of nicotiana benthamiana carotenoid cleavage dioxygenase 1 (CCD1) are respectively constructed; the agrobacterium tumefaciens of the three vectors are mixed and infiltrated into the boeng tobacco leaves to obtain the leaves for expressing the astaxanthin. According to the invention, the expression of the nicotiana benthamiana CCD1 gene is interfered while the AdKC and AdKeto genes are expressed in the nicotiana benthamiana leaves, so that the content of astaxanthin expressed in the nicotiana benthamiana leaves is increased.

Disclosed is a method of differentiating empty capsids from full capsids or loaded and unloaded non-viral gene therapy vectors in a viral preparation. The method comprises the steps of: a) providing a preparation of viral particles or gene therapy vectors; b) subjecting the preparation to interferometric scattering mass cytometry (ISCAMS) in an interferometric scattering microscope to generate mass distribution data of the viral particles; c) determining from the mass distribution data the level of empty capsids and capsids containing genomes or the level of loaded and unloaded vectors in the viral particles.

Non-viral gene therapy treatments have a number of advantages over viral vectors including typical non-antigenicity, low manufacturing cost, simplicity, and efficiency of delivering genetic cargo into the cytoplasm. The potency of non-viral gene therapy systems can be enhanced by providing them with means to more efficiently transport the delivered DNA from the cytoplasm to the nucleus. Provided herein, at least in part, are means of enhancing potency of non-viral gene therapies by including novel nuclear translocation enhancing sequences and compositions that can result in optimized nuclear translocation as well as related compositions and methods.

Provided are gene therapy vectors designated MEV-GTVs, which are MEVs that contain an ITR-containing plasmid (also referred to as a minigene plasmid) that comprises Inverted Terminal Repeats (ITRs), such as viral ITRs, and nucleic acid encoding a product of interest, and optionally regulatory sequences. The ITRs serve to circularize the minigene plasmid. The plasmids do not contain additional viral components, so that resulting DNA is not encapsulated in a viral capsid or envelop and is not replicated by viral genes. The plasmids can be inserted into bacterial plasmids for propagation.

This document relates to materials and methods for treating cancer. For example, this document provides materials and methods for using PD-L1 targeting domains in bispecific chimeric polypeptides, chimeric transmembrane polypeptides, genetically modified viruses, nucleic acid vectors, and / or fusion-inducing cells to treat cancer.

The present disclosure relates to a genetically modified virus comprising at least one nucleic acid molecule encoding a cytokine that recruits and / or activates T cells and a class II major histocompatibility complex transactivator (CIITA), as well as pharmaceutical compositions comprising said genetically modified virus and methods of treating cancer with said genetically modified virus.

This invention belongs to the field of aquaculture technology and relates to a novel use of capsaicin, particularly its use in the preparation of drugs and / or feed additives for the prevention and treatment of fish viral infections. The core of this invention lies in the significant protective effect of capsaicin against carp spring viremia virus (SVCV), grass carp reovirus (GCRV), and carp herpesvirus type 2 (CyHV-2) infections, effectively inhibiting the transcription of SVCV, GCRV, and CyHV-2 viral genes and the expression of viral proteins. Feed additives and / or drugs containing capsaicin can be used for the prevention and treatment of fish viral diseases, offering advantages such as high protective efficiency and environmental friendliness.

The present invention discloses an engineered circRNA encoding NGF protein, a pharmaceutical composition, and a preparation method and application thereof. The engineered circRNA encoding nerve growth factor (NGF) has the advantages of enhancing the stability and expression efficiency of NGF. By packaging the engineered circRNA in nanolipid particles (LNP), effective drug delivery and release can be achieved. The pharmaceutical composition can be applied by topical administration, gastrointestinal administration or parenteral administration to provide neuroprotection and treatment of nerve damage. A single administration has a significant neuroprotective effect, does not require continuous administration, and avoids the risk of viral infection of animal-derived proteins. Compared with viral gene delivery, one advantage of circRNA-based therapy is that mRNA will not be transported to the cell nucleus, thereby reducing the risk of sequence insertion into the genome and inducing carcinogenesis.

The present disclosure provides nucleic acid molecules comprising a first inverted terminal repeat (ITR), a second ITR, and a genetic cassette encoding a target sequence. In some embodiments, the target sequence encodes a miRNA and / or a therapeutic protein. In certain embodiments, the therapeutic protein comprises a clotting factor, a growth factor, a hormone, a cytokine, an antibody, a fragment thereof, and a combination thereof. In some embodiments, the first ITR and / or the second ITR is an ITR of a non-adeno-associated virus (AAV). The present disclosure also provides methods of treating a metabolic disorder of the liver in a subject comprising administering to the subject the nucleic acid molecule or a polypeptide encoded thereby.

Herein is reported a method for producing recombinant adeno-associated viral particle preparation (rAAVp) comprising the step of cultivating a mammalian cell comprising expression cassettes for a non-adeno-associated viral gene, which is interspaced between two AAV inverted terminal repeats (ITRs), an adeno-associated virus rep gene, an adeno-associated virus cap gene, an adeno-associated virus E1A gene, an adeno-associated virus E1B gene, an adeno-associated virus E2A gene, an adeno-associated virus E4orf6 and an adeno-associated virus VA RNA gene, and thereby producing the rAAVp, wherein the cultivating is at a pH value in the range of and including pH 7.4 to pH 7.6. The yield of the rAAVp produced by the cultivating at a pH value in the range of and including pH 7.4 to pH 7.6 is higher than the yield of a rAAVp produced by a cultivating at a pH value in the range of and including pH 7.0 to pH 7.2 and the rAAVp produced by the cultivating at a pH value in the range of and including pH 7.4 to pH 7.6 has a higher percentage of full particles than a rAAVp produced by a cultivating at a pH value in the range of and including pH 7.0 to pH 7.2.

The present disclosure provides a method of inhibiting telomerase activity to reduce human herpesvirus (e.g., HMCV, EBV, HSV-1, and / or HHV-6 / 7 / 8) replication. The method comprises treating cells with a telomerase inhibitor prior to and after HCMV infection. The telomerase inhibitor may be a pharmaceutical inhibitor such as BIBR1532 or MST312, or an siRNA construct targeting the hTERT catalytic subunit of telomerase. Treatment with the telomerase inhibitor results in reduced viral titer, decreased viral gene expression, and diminished viral protein levels across different temporal phases of herpesvirus infection. The method provides a novel approach for inhibiting herpesvirus replication through targeting of host cell telomerase activity.

The present invention relates to oncolytic vaccinia viruses and recombinant viruses and methods of use thereof. In particular, the present invention provides a cloned vaccinia virus strain exhibiting enhanced anti-tumor properties and / or reduced immunogenicity, as well as a recombinant vaccinia virus derived therefrom. The present invention also provides recombinant oncolytic virus strains comprising an inactivated mutation in one or more viral genes, and / or one or more heterologous nucleic acids each encoding one or more heterologous gene products. The viruses (e.g., vaccinia viruses, including recombinant vaccinia viruses) provided herein are useful as oncolytic viral therapies (e.g., oncolytic vaccinia viral therapies) for the treatment of cancer. The invention also provides pharmaceutical compositions of the virus, such as vaccinia virus, and methods and uses of the virus, such as vaccinia virus, for the treatment of cancer, as well as nucleic acids encoding the virus.

The invention discloses a fluorine-containing macrocyclic polyamine polymer based on valerolactone ring-opening polymerization as well as a preparation method and application of the fluorine-containing macrocyclic polyamine polymer. The fluorine-containing macrocyclic polyamine polymer based on valerolactone ring-opening polymerization is mainly prepared and synthesized by nucleophilic substitution, ring-opening polymerization, esterification reaction and click reaction. The oxygen carrying capacity is as high as 15 mg / L; singlet oxygen can be efficiently generated; siRNA can be effectively condensed; after the LipoTMRNAiMAX is compounded with auxiliary lipid (DSPE-PEG-iRGD) to form nano-particles, the transfection efficiency of the LipoTMRNAiMAX is 3 times that of LipoTMRNAiMAX after illumination under the condition of 10% serum; by delivering oxygen and HIF-1alpha, proliferation of 4T1 cells in a mouse body is remarkably inhibited, and the tumor inhibition rate reaches up to 87%. The fluorine-containing macrocyclic polyamine polymer based on valerolactone ring opening polymerization can be used for preparing a non-viral gene vector, serving as a photosensitizer and preparing a carrier for delivering oxygen and HIF-1alpha in tumor treatment.

This disclosure provides nucleic acid molecules comprising a first inverted terminal repeat (ITR), a second ITR, and a gene cassette encoding a target sequence. In some embodiments, the target sequence encodes a microRNA and / or a therapeutic protein. In certain embodiments, the therapeutic protein comprises a clotting factor, a growth factor, a hormone, a cytokine, an antibody, a fragment thereof, and a combination thereof. In some embodiments, the first ITR and / or the second ITR is an ITR of a non-adeno-associated virus (AAV). This disclosure also provides methods of treating a metabolic liver disorder in a subject comprising administering to the subject the nucleic acid molecule or a polypeptide so encoded.

The invention discloses an application of aspergillus versicolor exopolysaccharide AVP214-1 in preparation of a medicine for resisting Singapore grouper iridovirus. It is found that in an in-vitro experiment, the AVP214-1 can significantly reduce the cytopathy degree induced by Singapore grouper iridovirus (SGIV), and the transcriptional level and the protein level of viral genes MCP and VP19 are reduced; furthermore, the AVP214-1 is applied to grouper in-vivo experiments, the AVP214-1 also has a good anti-SGIV effect, and a tissue slice result shows that an AVP214-1 treatment group relieves liver and spleen histopathologic changes caused by SGIV infection, and can significantly reduce the transcriptional level of viral genes MCP, VP19 and ICP18. The research provided by the invention has an extremely important significance in preventing or treating the fish iridovirus disease caused by the iridovirus of Singapore grouper by utilizing the AVP214-1.

[Problem] The purpose of the present invention is to provide a modified adenovirus having a cytocidal activity on a target cell and high safety.[Solution] The present invention pertains to: a modified adenovirus which comprises an E1A gene, an enhancer sequence having a function of enhancing the expression of the E1A gene, and an AU-rich element introduced into the 3′-untranslated region of a viral gene, which is essentially required for the self-propagation thereof, or a position adjacent to the 3′-untranslated region, or a modified adenovirus which comprises an E1A gene and an enhancer sequence having a function of enhancing the expression of the E1A gene and cannot express normal E4orf6 protein, wherein the distance between the 5′-terminus of the E1A gene and the terminus of the enhancer sequence is 1500-4500 bp; and a medicine comprising the same.

Provided herein are compositions and methods for the viral gene therapy (e.g., AAV-directed gene therapy) of cholesterol storage diseases or disorders, such as Niemann-Pick disease, Type C.

This invention relates to oncolytic vaccinia viruses, recombinant viruses thereof, and methods of use. Specifically, the invention provides vaccinia virus clone lines and recombinant vaccinia viruses derived therefrom, said vaccinia virus clone lines exhibiting enhanced antitumor properties and / or reduced immunogenicity. The invention also provides recombinant oncolytic virus lines comprising inactivating mutations in one or more viral genes, and / or one or more heterologous nucleic acids each encoding one or more heterologous gene products. The viruses provided by this invention (such as vaccinia viruses, including recombinant vaccinia viruses) can be used as oncolytic virus therapies (such as oncolytic vaccinia virus therapy) for the treatment of cancer. The invention also provides pharmaceutical compositions of viruses (such as vaccinia viruses), methods and uses of viruses (such as vaccinia viruses) for the treatment of cancer, and nucleic acids encoding said viruses.

The invention discloses a cationic polymer gene delivery vector as well as a preparation method and application thereof, and the cationic polymer gene delivery vector is a polymer prepared from monomers with different hydrophilic and hydrophobic properties and polyglycidyl amine in two modes of block copolymerization and random copolymerization. The monomer polymerized with the polymer is at least one of propylene oxide, epoxybutane, epoxypentane, epoxyhexane, epoxyheptane and styrene oxide; wherein the number of the hydrophobic unit units in all repetitive units of the polymer accounts for 10%-50%. The cationic polymer gene delivery vector provided by the invention, as a non-viral gene transfection vector, has relatively low cytotoxicity and relatively good gene transfection capability.

The present invention relates to a chimeric poxvirus with improved anticancer activity (higher cancer cell killing capacities and better tumor selectivity), as well as variant version thereof with one or more altered viral genes, recombinant versions thereof comprise one or more nucleic acid(s) of interest and recombinant variant versions thereof, all of which may be included in a composition and used for the treatment of a disease, in particular proliferative disease, notably cancers.